BG107558A - Фармацевтична комбинация от ангиотензин ii антагонисти ii ангиотензин i конвертиращи ензимни инхибитори - Google Patents

Фармацевтична комбинация от ангиотензин ii антагонисти ii ангиотензин i конвертиращи ензимни инхибитори Download PDF

Info

Publication number
BG107558A
BG107558A BG107558A BG10755803A BG107558A BG 107558 A BG107558 A BG 107558A BG 107558 A BG107558 A BG 107558A BG 10755803 A BG10755803 A BG 10755803A BG 107558 A BG107558 A BG 107558A
Authority
BG
Bulgaria
Prior art keywords
ang
antagonist
ace inhibitor
ramipril
telmisartan
Prior art date
Application number
BG107558A
Other languages
Bulgarian (bg)
English (en)
Inventor
Peter Boehm
Wolf T. Meinicke
Axel Riedel
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co.Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32234234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG107558(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma Gmbh & Co.Kg filed Critical Boehringer Ingelheim Pharma Gmbh & Co.Kg
Publication of BG107558A publication Critical patent/BG107558A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
BG107558A 2000-08-22 2003-02-14 Фармацевтична комбинация от ангиотензин ii антагонисти ii ангиотензин i конвертиращи ензимни инхибитори BG107558A (bg)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0020691.2A GB0020691D0 (en) 2000-08-22 2000-08-22 Pharmaceutical combination
DE10108215A DE10108215A1 (de) 2000-08-22 2001-02-20 Pharmazeutische Kombination von Antagonisten von Angiotensin II und Hemmern von Angiotensin II konvertierendem Enzym
PCT/EP2001/009428 WO2002015891A2 (en) 2000-08-22 2001-08-16 Pharmaceutical combination of angiotensin ii antagonists and ace inhibitors
CA002372785A CA2372785A1 (en) 2000-08-22 2002-02-21 Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors
JP2002093288A JP2003238444A (ja) 2000-08-22 2002-02-21 アンギオテンシンｉｉ拮抗剤及びアンギオテンシンｉ変換酵素阻害剤の医薬組成物

Publications (1)

Publication Number Publication Date
BG107558A true BG107558A (bg) 2004-01-30

Family

ID=32234234

Family Applications (1)

Application Number Title Priority Date Filing Date
BG107558A BG107558A (bg) 2000-08-22 2003-02-14 Фармацевтична комбинация от ангиотензин ii антагонисти ii ангиотензин i конвертиращи ензимни инхибитори

Country Status (15)

Country Link
US (1) US20030171415A1 (enExample)
EP (1) EP1313468A2 (enExample)
JP (1) JP2003238444A (enExample)
CN (1) CN1447691A (enExample)
AU (1) AU2001295465B2 (enExample)
BG (1) BG107558A (enExample)
BR (1) BR0113321A (enExample)
CA (2) CA2415788A1 (enExample)
CZ (1) CZ2003534A3 (enExample)
DE (1) DE10108215A1 (enExample)
GB (1) GB0020691D0 (enExample)
IL (1) IL153937A0 (enExample)
NO (1) NO20030761L (enExample)
SK (1) SK2062003A3 (enExample)
WO (1) WO2002015891A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
HUP0203326A3 (en) * 1999-08-30 2003-04-28 Sanofi Aventis Deutschland Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
US20040157911A1 (en) * 1999-08-31 2004-08-12 Spiridon Spireas Storage-stable and bio-stable formulations of ace inhibitors, and methods for preparation thereof
US20040248968A1 (en) * 2002-02-20 2004-12-09 Boehringer Ingelheim International Gmbh Pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors
DE10301371A1 (de) * 2003-01-16 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten
US9029363B2 (en) * 2003-04-30 2015-05-12 Boehringer Ingelheim International Gmbh Telmisartan sodium salt pharmaceutical formulation
US20050004194A1 (en) * 2003-05-15 2005-01-06 Graves Kurt Chum Use of organic compounds
US20040265238A1 (en) 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
SE0302331D0 (sv) * 2003-08-29 2003-08-29 Astrazeneca Ab New use II
DE102004008804A1 (de) * 2004-02-20 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mehrschichttablette
WO2005097109A1 (en) * 2004-04-01 2005-10-20 Daniel Batlle Methods for achieving a protective ace2 expression level
CA2568640C (en) 2004-06-04 2011-08-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
EP1723962A1 (en) 2005-05-19 2006-11-22 IMBA-Institut für Molekulare Biotechnologie GmbH Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries
US8080534B2 (en) * 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
WO2009087116A1 (en) * 2008-01-11 2009-07-16 Novartis Ag Use of spp100 for the treatment of acute mi
PE20091809A1 (es) 2008-04-17 2009-12-03 Sanofi Aventis Uso de dronedarona para la preparacion de un medicamento para uso en la prevencion de la hospitalizacion cardiovascular o de la mortalidad
EP2116239A1 (en) * 2008-04-29 2009-11-11 Sanofi-Aventis Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment
CN101869710A (zh) * 2009-04-24 2010-10-27 北京奥萨医药研究中心有限公司 降压药物组合物
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
US20140170158A1 (en) * 2012-12-17 2014-06-19 The Johns Hopkins University Compositions and methods for treating or preventing lung diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821232A (en) * 1990-05-11 1998-10-13 Pfizer Inc. Synergistic therapeutic compositions and methods
EP0629408A1 (en) * 1993-06-16 1994-12-21 LABORATOIRES MERCK, SHARP & DOHME-CHIBRET Combination of angiotensin converting enzyme inhibitors and AII antagonists
WO1996031234A1 (en) * 1995-04-07 1996-10-10 Novartis Ag Combination compositions containing benazepril or benazeprilat and valsartan
CA2224451A1 (en) * 1995-06-30 1997-01-23 Merck & Co., Inc. Method of treating renal disease using an ace inhibitor and an aii antagonist
ATE216881T1 (de) * 1996-06-24 2002-05-15 Merck & Co Inc Zusammensetzung auf basis von enalapril und losartan
US6465502B1 (en) * 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
HUP0203326A3 (en) * 1999-08-30 2003-04-28 Sanofi Aventis Deutschland Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events

Also Published As

Publication number Publication date
CN1447691A (zh) 2003-10-08
CZ2003534A3 (cs) 2003-06-18
AU2001295465B2 (en) 2007-12-13
WO2002015891A3 (en) 2002-06-13
US20030171415A1 (en) 2003-09-11
JP2003238444A (ja) 2003-08-27
DE10108215A1 (de) 2002-08-22
BR0113321A (pt) 2003-07-15
SK2062003A3 (en) 2003-08-05
NO20030761D0 (no) 2003-02-18
GB0020691D0 (en) 2000-10-11
EP1313468A2 (en) 2003-05-28
WO2002015891A2 (en) 2002-02-28
IL153937A0 (en) 2003-07-31
CA2372785A1 (en) 2003-08-21
AU9546501A (en) 2002-03-04
NO20030761L (no) 2003-02-18
CA2415788A1 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
AU2001295465B2 (en) Pharmaceutical combination of angiotensin II antagonists and ace inhibitors
AU2001295465A1 (en) Pharmaceutical combination of angiotensin II antagonists and ace inhibitors
US11000575B2 (en) Use of hyaluronidase for the prevention or treatment of arterial hypertension or cardiac insufficiency
ZA200503542B (en) Pharmaceutical combination of telmisartan and atovastatin for the prophylaxis of treatment of cardiovascular, cardiopulmonary, pulmanory or renal diseases
AU716519B2 (en) Method of treating renal disease using an ace inhibitor and an A II antagonist
EP0641218B1 (en) Use of angiotensin antagonist (at1) for reducing post myocardial infarct mobidity and mortality
ES2287689T3 (es) Combinacion farmaceutica para la prevencion o terapia de enfermedades cardiovasculares, cardiopulmonares, pulmonares o renales.
US20080146639A1 (en) Pharmaceutical Combination of Angiotensin II Antagonists and Angiotensin I Converting Enzyme Inhibitors
US6329384B1 (en) Endothelin antagonist and renin-angiotensin system inhibitor as a combined preparation
US20080114046A1 (en) Pharmaceutical Combination of Angiotensin II Antagonists and Angiotensin I Converting Enzyme Inhibitors
US20030158223A1 (en) Pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors
Weir Angiotensin-II receptor antagonist: A new class of antihypertensive agents.
ZA200300556B (en) Pharmaceutical combination of angiotensin II antagonists and ace inhibitors.
AU2007237280A1 (en) Pharmaceutical combination of Angiotensin II antagonists and Angiotensin I converting enzyme inhibitors
HK1104976A (en) Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors
KR20140116879A (ko) (3s,3s'') 4,4''-디설판디일비스(3-아미노부탄 1-설폰산) 및 제2 항고혈압제의 조합
EP1478397A1 (en) Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors
Andersen et al. Inhibition of the renin-angiotensin system, with particular reference to dual blockade treatment
HK1057487A (en) Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors
Sleight PPOGRESS beyond HOPE and LIFE: The ONTARGET trial programme
Veglio et al. Combinations of renin-angiotensin-aldosterone system antagonists: true advantages?
Mbah Angiotensin II Receptor Antagonists: The Utility of the Therapeutic Agents in Clinical Practice
JP2004520268A5 (enExample)
KR20030069693A (ko) 안지오텐신 ⅱ 길항제 및 안지오텐신 ⅰ 전환효소억제제의 약제학적 배합물
Tiwaskar End organ protection